Download interactions: TXT MITAB-2.5
| Interaction | Interactor | Experiments | Homologs | Category | Interaction Score |
Confidence |
|---|---|---|---|---|---|---|
|
FIBA
Fibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha chain] |
1 |
2 |
High-throughput |
0.691 | High |
|
|
FIBB
Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain] |
1 |
2 |
High-throughput |
0.691 | High |
|
|
FIBG
Fibrinogen gamma chain |
1 |
2 |
High-throughput |
0.691 | High |
|
|
A1AT
Alpha-1-antitrypsin |
1 |
0 |
High-throughput |
0.656 | High |
|
|
A1AG1
Alpha-1-acid glycoprotein 1 |
1 |
0 |
High-throughput |
0.656 | High |
|
|
IGLL5
Immunoglobulin lambda-like polypeptide 5 |
1 |
6 |
High-throughput |
0.618 | High |
|
|
SPB5
Serpin B5 |
1 |
1 |
High-throughput |
0.618 | High |
|
|
IGKC
Immunoglobulin kappa constant |
1 |
7 |
High-throughput |
0.575 | High |
|
|
IGHG1
Immunoglobulin heavy constant gamma 1 |
1 |
12 |
High-throughput |
0.575 | High |
|
|
IGHG2
Immunoglobulin heavy constant gamma 2 |
1 |
16 |
High-throughput |
0.575 | High |
|
|
HPT
Haptoglobin |
1 |
2 |
High-throughput |
0.536 | High |
|
|
CO3
Complement C3 |
1 |
2 |
High-throughput |
0.536 | High |
|
|
TRFE
Serotransferrin |
1 |
1 |
High-throughput |
0.536 | High |
|
|
APOA1
Apolipoprotein A-I |
1 |
0 |
High-throughput |
0.513 | High |
|
|
HBB
Hemoglobin subunit beta |
1 |
0 |
High-throughput |
0.513 | High |
|
|
PEPL
Periplakin |
1 |
13 |
High-throughput |
0.489 | High |
|
|
CRYAB
Alpha-crystallin B chain |
1 |
5 |
High-throughput |
0.489 | High |
|
|
INVO
Involucrin |
1 |
7 |
High-throughput |
0.489 | High |
|
|
LEG7
Galectin-7 |
1 |
15 |
High-throughput |
0.489 | High |
|
|
EVPL
Envoplakin |
1 |
13 |
High-throughput |
0.489 | High |
|
|
FZR1
Fizzy-related protein homolog |
1 |
2 |
High-throughput |
0.437 | High |
|
|
VATL
V-type proton ATPase 16 kDa proteolipid subunit c |
1 |
0 |
High-throughput |
0.279 | Low |
|
|
POF1B
Protein POF1B |
1 |
0 |
High-throughput |
0.279 | Low |
Service provided by Combinatics, Japan
Last updated: 11Aug2025
